Sofie Biosciences, the molecular imaging company, has announced their acquisition of Zevacor Pharma, previously known as IBA Molecular North America. This deal will combine the two companies under the name SOFIE and continue Zevacor's commitment to customers. The acquisition was completed in May 2017 for an undisclosed amount and was funded by a $27.4 million round. SOFIE plans to unite Zevacor's team and manufacturing capabilities with their own, strengthening their position in the market. As part of the acquisition, SOFIE acquired Zevacor's 15 site network for manufacturing and contract manufacturing.